2024-514381-39-00招募中3 期
LEAP2MONO - EFC17215 A phase 3, multicenter, multinational, randomized, double-blind, double-dummy, active-comparator study to evaluate the efficacy and safety of venglustat in adult and pediatric patients with Gaucher disease Type 3 (GD3) who have reached therapeutic goals with Enzyme Replacement Therapy (ERT)
Sanofi-Aventis Recherche & Developpement4 个研究点 分布在 3 个国家目标入组 15 人开始时间: 2024年7月31日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 15
- 试验地点
- 4
- 主要终点
- Change in Scale for Assessment and Rating of Ataxia (SARA) modified total score
研究概览
简要总结
Evaluate the efficacy of venglustat compared to Cerezyme in adult and pediatric (12-<18 years) GD3 patients by assessing:
- Ataxia using the Scale for the Assessment and Rating of Ataxia (SARA)
- Cognition using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)
入排标准
- 年龄范围
- 0 years 至 64 years（0-17 Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- •The participant has received ERT (Cerezyme or other ERT; as deemed appropriate by local regulations) for at least 3 years prior to enrollment, on a stable dose for at least 6 months, is deemed clinically stable for at least 1 year by the Investigator and is within the therapeutic goals as all of the following: - Hemoglobin level of ≥11.0 g/dL for females and ≥12.0 g/dL for males - Platelet count ≥100 000/mm3 - Spleen volume <10 multiples of normal (MN) - Liver volume <1.5 MN - No bone crisis and free of symptomatic bone disease such as bone pain attributable to osteonecrosis and/or pathological fractures within 3 months prior to screening
- •Signed written informed assent/consent
- •Adult participant is ≥18 years of age
- •Pediatric participant is ≥12 years <18 years of age
- •The participant has a clinical diagnosis of GD3 and a documented deficiency of acid beta-glucosidase activity confirming this diagnosis.
- •The participant has a modified SARA score of 1 or above.
- •The presence of gaze palsy, predominantly horizontal, with slow or absent saccades.
- •If the participant has a history of seizures, they are well controlled under appropriate medication not identified as a strong or moderate inducer or inhibitor of CYP3A.
- •Participants ≥ 30 kg of weight
- •Contraception for sexually active male or female participants; not pregnant or breastfeeding; no sperm donating for male participant
排除标准
- •The participant is blood transfusion-dependent.
- •The participant is scheduled for in-patient hospitalization including elective surgery, during the study.
- •The participant has had a major organ transplant (eg, bone marrow or liver).
- •A history of drug and/or alcohol abuse within the past year prior to the screening visit.
- •Chaperone therapy within 6 months, substrate reduction therapy other than venglustat within 6 months or venglustat substrate reduction therapy prior to enrollment.
- •Exposure to any investigational drug within the last 30 days or 5 half-lives from screening, whichever is longer
- •The participant has received strong or moderate inducers or inhibitors of CYP3A within 14 days or 5 half-lives from screening, whichever is longer, prior to screening. This also includes the consumption of grapefruit, grapefruit juice, or grapefruit containing products within 72 hours of starting venglustat. The participant is unwilling to abstain from consumption of grapefruit, grapefruit juice, or grapefruit containing products for the duration of the treatment period.
- •The participant, in the opinion of the investigator, is unable to adhere to the requirements of the study or unable to undergo study assessments (eg, contraindication for MRI).
- •Type of participant and disease characteristic: the participant has had a total splenectomy prior to enrollment. The patient had a partial splenectomy within 3 years prior to randomization.
- •Participant not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions, or participants potentially at risk of noncompliance to study procedures.
- •Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the Investigator, contraindicates participation in the study
- •Prior esophageal varices or liver infarction or current liver enzymes (alanine aminotransferase [ALT]/ aspartate aminotransferase [AST]) or total bilirubin >2 times the upper limit of normal, unless the participant has a diagnosis of Gilbert Syndrome.
- •The participant has any clinically significant disease, other than GD, including cardiovascular (congenital cardiac defect, coronary artery disease, valve disease or left sided heart failure; clinically significant arrhythmias or conduction defect), hepatic, gastrointestinal, pulmonary, neurologic, endocrine, metabolic (eg, hypokalemia, hypomagnesemia) or psychiatric disease, other medical conditions, or serious intercurrent illnesses that may preclude participation in the opinion of the Investigator.
- •The participant has renal insufficiency, as defined by an estimated glomerular filtration rate <30 mL/min/1.73m2 at the screening visit.
- •The participant has a history of cancer, except for basal cell carcinoma.
- •The participant has progressive myoclonic epilepsy.
- •The participant is pregnant (has a positive serum beta-human chronic gonadotropin [β-hCG]) or lactating.
- •The participant requires use of invasive ventilatory support.
- •The participant requires use of noninvasive ventilator support while awake for longer than 12 hours daily.
结局指标
主要结局
Change in Scale for Assessment and Rating of Ataxia (SARA) modified total score
Change in Scale for Assessment and Rating of Ataxia (SARA) modified total score
Change in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) total scale index score
Change in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) total scale index score
次要结局
- Percent change in spleen volume
- Percent change in liver volume
- Change in hemoglobin level
- Percent change in platelet count
- Percent change in CSF GL-1 and lyso-GL-1 levels
- Percent change in plasma GL-1 and lyso-GL-1 levels
- Number of patients with treatment emergent adverse events (TEAEs)/ serious adverse events (SAEs)/ adverse events of special interest (AESIs)
- Change in score of Beck Depression Inventory II (BDI-II) during the treatment-emergent period (for participants 13 years of age and above at baseline)
- Change in Patient Health Questionnaire 9 (PHQ-9) during the treatment-emergent period (for participants 12 years of age at baseline)
研究者
Clinical Sciences and Operations
Scientific
Sanofi-Aventis Recherche & Developpement
研究点 (4)
Loading locations...
相似试验
招募中
2 期
Guanabenz in VWM2023-503320-89-00Amsterdam UMC40
已完成
3 期
A Phase 3, Open-Label, Single-arm, Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Activity, and Safety of Ravulizumab Administered Subcutaneously in Pediatric Participants (2 to < 18 years of age) with Paroxysmal Nocturnal Hemoglobinuria (PNH) or Atypical Hemolytic Uremic Syndrome (aHUS)2022-502335-19-00Alexion Pharmaceuticals Inc.14
招募中
2 期
A multicentre trial evaluating the combination of a MEK inhibitor and a
PDL1 inhibitor in pediatric and adult patients with locally advanced and/or
metastatic soft tissue sarcoma2024-510712-75-00Centre Leon Berard80
招募中
3 期
A study to compare Venetoclax Azacitidine and Quizartinib Vs Venetoclax and Azacitidine in newly diagnosed acute myeloid leukemia patient´s ineligible for standard induction chemotherapyAcute myeloid leukemia2025-522979-29-00Fundacion PETHEMA350
招募中
3 期
A Randomized, Placebo‐Controlled Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts‐2Acute myeloid leukemia2023-507518-28-00Universitaetsklinikum Ulm AöR423